References
- BennettJLStuveOUpdate on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implicationsClin Neuropharmacol20093212113219483479
- LublinFDReingoldSCDefining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple SclerosisNeurology1996469079118780061
- JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol1996392852948602746
- JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trialNeurology199545126812767617181
- PRISMS Study GroupRandomised, double-blind, placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosisLancet Neurol199835214981504
- The IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology1993436556618469318
- KapposLTraboulseeAConstantinescuCLong-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology20066794495317000959
- PRISMS Study Group, University of British Columbia MS/MRI Analysis GroupPRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MSNeurology2001561628163611425926
- CostelloKKennedyPScanzilloJRecognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long termMedscape J Med20081022519008986
- CoxDStoneJManaging self-injection difficulties in patients with relapsing-remitting multiple sclerosisJ Neurosci Nurs20063816717116817668
- MohrDCBoudewynACLikoskyWInjectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-injectAnn Behav Med20012312513211394554
- TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol200925656857619444532
- TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology20036155155412939437
- Al-SabbaghABennetRKozmaCMedication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care databaseJ Neurol2008255Suppl 2S79
- World Health OrganizationAdherence to long-term therapies: evidence for action Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/index.htmlAccessed August 24, 2011
- LugaresiAAddressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivationExpert Opin Drug Deliv20096995100219637982
- CramerJACuffelBJDivanVPatient satisfaction with an injection device for multiple sclerosis treatmentActa Neurol Scand200611315616216441244
- MikolDLopez-BresnahanMTaraskiewiczSA randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by auto-injection or manual injection in relapsing-remitting multiple sclerosisMult Scler20051158559116193898
- DevonshireVArbizuTBorreBPatient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyBMC Neurol2010102820433746
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human UseGuideline for Good Clinical Practice E6(R1) Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1_Guideline.pdfAccessed July 11, 2011
- The European Parliament and the Council of the European UnionDirective 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use Available from: http://www.eortc.be/Services/Doc/clinical-EU-directive-04-April-01.pdfAccessed July 11, 2011
- World Medical AssociationDeclaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects1996
- Association of British NeurologistsRevised (2009) Association of British Neurologists’ guidelines for prescribing in multiple sclerosis Available from: http://www.abn.org.uk/abn/userfiles/file/ABN_MS_Guidelines_2009_Final(1).pdfAccessed July 21, 2011
- PolmanCHReingoldSCEdanGDiagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Ann Neurol20055884084616283615
- ExellSVerdunEDriebergenRA new electronic device for subcutaneous injection of IFN beta-1aExpert Rev Med Devices2011854355321728909
- Merck Serono Launches RebiSmart™, First Electronic Injection Device For Delivery of Multiple Sclerosis Treatment Rebif®News releaseJune 242009 Available from: http://www.merckserono.com/corp.merckserono/en/images/20090624_en_tcm112_42119.pdfAccessed July 11, 2011
- National Audit OfficePrescribing costs in primary care Available from: http://www.nao.org.uk/publications/0607/prescribing_costs_in_primary_c.aspxAccessed February 24, 2011
- BruceJMHancockLMLynchSGObjective adherence monitoring in multiple sclerosis: initial validation and association with self-reportMult Scler20101611212019995835